Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE
PreviousNext
Research Articles, Development/Plasticity/Repair

Neuroendocrine Mechanisms Governing Sex Differences in Hyperalgesic Priming Involve Prolactin Receptor Sensory Neuron Signaling

Candler Paige, Priscilla A. Barba-Escobedo, Jennifer Mecklenburg, Mayur Patil, Vincent Goffin, David R. Grattan, Gregory Dussor, Armen N. Akopian and Theodore J. Price
Journal of Neuroscience 9 September 2020, 40 (37) 7080-7090; DOI: https://doi.org/10.1523/JNEUROSCI.1499-20.2020
Candler Paige
1School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, Texas 75080
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priscilla A. Barba-Escobedo
2Departments of Endodontics, School of Dentistry, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Mecklenburg
2Departments of Endodontics, School of Dentistry, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mayur Patil
2Departments of Endodontics, School of Dentistry, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Goffin
3Université de Paris, Institut National de la Santé et de la Recherche Médicale U1151, Paris, 75014, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Grattan
4Centre for Neuroendocrinology and Department of Anatomy, University of Otago School of Biomedical Sciences, Dunedin 09001, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David R. Grattan
Gregory Dussor
1School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, Texas 75080
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gregory Dussor
Armen N. Akopian
2Departments of Endodontics, School of Dentistry, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theodore J. Price
1School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, Texas 75080
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Theodore J. Price
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Many clinical and preclinical studies report higher prevalence and severity of chronic pain in females. We used hyperalgesic priming with interleukin 6 (IL-6) priming and PGE2 as a second stimulus as a model for pain chronicity. Intraplantar IL-6 induced hypersensitivity was similar in magnitude and duration in both males and females, while both paw and intrathecal PGE2 hypersensitivity was more persistent in females. This difference in PGE2 response was dependent on both circulating estrogen and translation regulation signaling in the spinal cord. In males, the duration of hypersensitivity was regulated by testosterone. Since the prolactin receptor (Prlr) is regulated by reproductive hormones and is female-selectively activated in sensory neurons, we evaluated whether Prlr signaling contributes to hyperalgesic priming. Using ΔPRL, a competitive Prlr antagonist, and a mouse line with ablated Prlr in the Nav1.8 sensory neuronal population, we show that Prlr in sensory neurons is necessary for the development of hyperalgesic priming in female, but not male, mice. Overall, sex-specific mechanisms in the initiation and maintenance of chronic pain are regulated by the neuroendocrine system and, specifically, sensory neuronal Prlr signaling.

SIGNIFICANCE STATEMENT Females are more likely to experience chronic pain than males, but the mechanisms that underlie this sex difference are not completely understood. Here, we demonstrate that the duration of mechanical hypersensitivity is dependent on circulating sex hormones in mice, where estrogen caused an extension of sensitivity and testosterone was responsible for a decrease in the duration of the hyperalgesic priming model of chronic pain. Additionally, we demonstrated that prolactin receptor expression in Nav1.8+ neurons was necessary for hyperalgesic priming in female, but not male, mice. Our work demonstrates a female-specific mechanism for the promotion of chronic pain involving the neuroendrocrine system and mediated by sensory neuronal prolactin receptor.

  • estrogen
  • nociceptor
  • prolactin
  • sex dimorphism
  • testosterone
  • translation regulation

Introduction

Many chronic pain conditions, such as migraine, fibromyalgia, temporomandibular joint disorders, irritable bowel syndrome, and rheumatoid arthritis, have a 2- to 6-fold greater prevalence or symptom severity in women compared with men (Unruh, 1996; Berkley, 1997; Fillingim et al., 2009; Traub and Ji, 2013). Pain symptoms in women with these chronic pain conditions can change during the menstrual cycle as gonadal hormone concentrations fluctuate; and some, but not all, pain conditions decrease in frequency or intensity after menopause (Houghton et al., 2002; LeResche et al., 2003; Slade et al., 2011; Mathew et al., 2013). There is a general consensus that plasticity mechanisms in peripheral and central nociceptive pathways are critical for chronic pain development in males and females, but the precise mechanisms governing this plasticity are increasingly recognized as sex dimorphic and are still largely unknown. Nevertheless, recent progress was made in understanding underlying mechanisms for sex-dependent mechanisms of nociceptive plasticity (Mogil et al., 2011; Sorge et al., 2011, 2015; Rosen et al., 2017; Martin et al., 2019). These findings on sex differences in nociceptive plasticity mechanisms, combined with abundant clinical and rodent data on the effects of gonadal hormones on pain, indicate a critical role for gonadal hormones in regulation of pain chronification (Fillingim et al., 2009; Traub and Ji, 2013).

Clearly, there are gonadal hormone-regulated mechanisms that promote chronic pain in females, but these mechanisms have not been thoroughly characterized. Prolactin (PRL) and its receptor (Prlr) are prime candidates for this potential mechanism, since responsiveness to PRL in a variety of cells, including sensory neurons, is closely regulated by estrogen (Childs et al., 1999; Pi and Voogt, 2002; Diogenes et al., 2006; Belugin et al., 2013). Thus, Prlr signaling sensitizes pain-related ion channels and causes increased excitability in nociceptors, specifically in females (Diogenes et al., 2006; Patil et al., 2013b, 2019a,b; Liu et al., 2016). Moreover, Prlr function in female nociceptors is governed by estrogen signaling via a nongenomic pathway that involves sex-specific translation of Prlr mRNA (Patil et al., 2019b). Clinically, high PRL levels are linked to migraine, and blocking PRL actions in women with hyperprolactinemia resolves headache (Silberstein, 1992; Cavestro et al., 2006; Oliveira et al., 2020). Based on these previous studies, we hypothesized that Prlr signaling might differentially contribute to female-specific regulation of chronic pain that can be assessed by use of the hyperalgesic priming model (Aley et al., 2000). Our work reveals that initiation, maintenance, and magnitude of hyperalgesic priming are governed by estrogen-dependent regulation of Prlr signaling in sensory neurons. Therefore, PRL signaling to Prlr is a gonadal hormone-dependent mechanism that promotes plasticity in the nociceptive pathway, supporting development of chronic pain specifically in females.

Materials and Methods

Animals

All animal experiments were approved by the University Texas Health Science Center at San Antonio and University of Texas at Dallas Institutional Animal Care and Use Committee. We followed guidelines issued by the National Institutes of Health and the Society for Neuroscience to minimize suffering and the number of animals used.

Key reagents and mouse lines

Eight- to 12-week-old female and male mice were purchased from The Jackson Laboratory. Ovariectomized (OVX) and gonadectomized (GdX) mice were purchased from The Jackson Laboratory. The estrous phases in adult females were determine by vaginal gavage as described by Caligioni (2009). Estrogen and testosterone replacement procedures to generate OVX-E-2 and GdX-T mice were performed as previously described (Diogenes et al., 2006; Nettleship et al., 2007). 17β-Estradiol (E-2; 300 µg per injection) or testosterone (T; 300 µg per injection) was injected intraperitoneally 2 times a week for 3 weeks into OVX and GdX mice, respectively.

The Prlrfl/fl line was generated as previously described (Brown et al., 2016). Prlrfl/fl line has inverse lox sites; hence, Cre recombination ablates the Prlr gene and activates GFP in targeted cells.

Estrogen was purchased from Sigma Millipore (catalog #PHR1353-1G) Testosterone was purchased from Sigma Millipore (catalog #T1875-1G). 4EGI was purchased from Tocris Bioscience. Vehicle for IL-6, PGE2, PRL, and Δ1-9-G129R-hPRL (ΔPRL) was 0.9% saline or PBS. Vehicle for 4EGI-1 was 0.1% DMSO in 0.9% saline.

Human PRL was generated in an Escherichia coli expression system containing plasmid with human PRL (Goffin; Institut National de la Santé et de la Recherche Médicale). Thus, PRL is fully processed, unmodified (i.e., no glycosylation and phosphorylation), and has molecular weight of ∼23 kDa. The Prlr antagonist ΔPRL (Rouet et al., 2010), which is a modified PRL that binds to and blocks the function of Prlr in rat, mouse, and human (Bernichtein et al., 2003), was also synthesized by Goffin (Institut National de la Santé et de la Recherche Médicale). We and others thoroughly confirmed the specificity of ΔPRL using in vitro (Bernichtein et al., 2003; Scotland et al., 2011), and in vivo studies (Rouet et al., 2010), including using Prlr KO mice (Belugin et al., 2013).

RT-PCR

RT-PCR was performed on hindpaw, L3-L5 DRG, and spinal cord (SC) total RNA. Dissected tissue was stored in RNA. Later at −20°C (QIAGEN). RNA extraction was done using the QIAzol lysis reagent and the RNAeasy Mini Kit (QIAGEN), and manufacturer's instructions were followed. cDNA was synthesized using Superscript III First Strand Synthesis kit (Invitrogen). Primers were as follows: Prlr-F (5′-CCATTCACCTGCTGGTGGAATCCT-3′), GFP-F (5′-AAGGCTACGTCCAGGAGCGCACCA-3′), GFP-R1 (5′-CGTCCTCGATGTTGTGGCGGATC-3′),and GFP-R2 (5′-TGGTGCGCTCCTGGACGTAGCCTT-3′). Amplification of target sequences was detected on 1 or 1.5% agarose gel depending on band size.

Behavior experiments

Hyperalgesic priming was established using a previously described model (Aley et al., 2000; Kim et al., 2016). IL-6 was injected intraplantarly, which created a transient mechanical hypersensitivity and initiated hyperalgesic priming. After IL-6-induced mechanical hypersensitivity resolved and thresholds returned to a baseline level, PGE2 was administered either intraplantarly or intrathecally to precipitate the primed state and induce mechanical hypersensitivity. PRL, ΔPRL, or 4EGI-1 was administered immediately before IL-6 or PGE2 administration. To evaluate mechanical hypersensitivity following the intraplantar or intrathecal injections, animals were habituated for 45-60 min in elevated behavior racks, and then paw withdraw threshold was determined using the up-down von Frey method (Chaplan et al., 1994). Both the experimenters performing the behavior and data analysis were done blinded.

Experimental design and statistical analysis

GraphPad Prism 7.0 (GraphPad) was used for all statistical analyses of data. Data are presented as mean ± SEM, with n indicating the number of independent animals per group in behavioral experiments. The sex of the animals used in each experiment is described in the text. Differences between groups were assessed by either mixed-effects or repeated-measures ANOVA with Bonferroni post hoc tests (noted for each figure). Statistical significance was determined as p < 0.05. Interaction F ratios and the associated p values are reported in the text.

Results

Sex differences in hyperalgesic priming in mice are regulated by gonadal hormones and translation regulation

Chronic pain occurs more frequently in females (Unruh, 1996; Berkley, 1997; Fillingim et al., 2009; Traub and Ji, 2013). This difference could be mediated by sex-dependent mechanisms controlling the transition from acute to chronic pain. We used the hyperalgesic priming paradigm (Aley et al., 2000) to gain insight into female-specific mechanisms involved in the acute to chronic pain transition. In our experiments, hyperalgesic priming was initiated with an intraplantar injection of IL-6 (0.5 ng). When the initial hypersensitivity from this IL-6 injection had resolved, the presence of priming was assessed with either an intraplantar or intrathecal injection of PGE2 (0.1 µg; Fig. 1A). Female C57BL/6 mice that were primed with IL-6 and then subsequently received an intraplantar injection of PGE2 had a slightly longer persistence of mechanical hypersensitivity compared with males (repeated-measures ANOVA; F(11,88) = 1.437; p = 0.1708; n = 5; Fig. 1B). Intrathecal injection of PGE2 in females had a significantly longer duration of response to PGE2 compared with males (repeated-measures ANOVA; F(14,91) = 8.975 p < 0.0001 n = 5; Fig. 1C). To rule out a possible strain-dependent sex effect, the experiment with spinal administration of PGE2 following intraplantar IL-6 was repeated in male and female Swiss Webster mice. The difference in the length of the PGE2 response following intrathecal administration was even longer lasting in this outbred strain (repeated-measures ANOVA; F(10,140) = 8.409; p < 0.0001; n = 8; Fig. 1D). To gain insight into the mechanistic underpinnings of the sex difference we identified, we did the remaining experiments with intraplantar injection of IL-6 and intrathecal administration of PGE2 in C57BL/6 mice.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Persistence of hyperalgesic priming is greater in female mice. A, Schematic of the IL-6-induced hyperalgesic priming model. BL, Baseline measurements. Brown arrows indicate injection time points. Blue arrows indicate post-PGE2 mechanical nociception measurement time points. B, Hyperalgesic priming model: IL-6 priming into paw and PGE2 injection into paw of female and male C57BL/6 mice. C, Hyperalgesic priming model: IL-6 priming into paw and PGE2 injection into SC of female and male C57BL/6 mice. D, The same model as in C in female and male Institute of Cancer Research (ICR) mice. Arrows indicate injection time points for IL-6/Veh and PGE2. Repeated-measures ANOVA with Bonferroni post hoc test: C, IL-6 male compared with Veh-female: ****p < 0.0001; IL-6 female compared with Veh-female: ★★★★p < 0.0001; ★★★p < 0.001; all others: *p < 0.05; ****p < 0.0001. n = 5–8.

In the above and following experiments, the female animals were all in the estrous phase of the estrous cycle at the time of IL-6 injections. The hyperalgesic priming model lasts at least a week; and despite controlling for the estrous phase at the time of IL-6 injection, female mice cycle quickly (4-5 d) through other phases of the cycle, and circulating blood estrogen (E-2) levels will vary on a day-to-day basis. Hence, to control for E-2 levels, we used OVX and OVX with E-2 supplementation (OVX-E-2) female mice. The substantial reduction of circulating E-2 in OVX mice (Green et al., 2016) did not change the initiation phase of priming, but the persistence of the response following the PGE2 injection was significantly shorter (mixed-measures ANOVA; F(34,220) = 8.710 p = 0.0011; n = 5 or 6; Fig. 2A). Administering E-2 to keep circulating E-2 at approximately proestrus phase levels in OVX-E-2 mice (Green et al., 2016) resulted in a significant extension of both the initiation (IL-6) and priming (PGE2) phases compared with intact females in the hyperalgesic priming model. Testosterone mediates male-specific nociceptive responses (Sorge et al., 2011). GdX mice have almost no circulating testosterone (Green et al., 2016). These GdX mice had a substantially longer response to IL-6 injection than intact male mice. Males with IL-6-induced mechanical hypersensitivity usually return to baseline mechanical sensitivity within 4-5 d (Kim et al., 2016) (Fig. 1B–D). In contrast, the initiation phase of hyperalgesic priming lasted >31 d in GdX males, and only partially recovered to baseline levels, which we displayed on a separate graph (Fig. 2B). The PGE2 phase was also lengthened in GdX compared with intact male mice (repeated-measures ANOVA; F(12,84) = 5.016; p < 0.0001; n = 5 or 6; Fig. 2C). Testosterone rescue in GdX-T animals returned the initiation and priming phases to the same timeline as intact males (Fig. 2C). These results show that the time course of hyperalgesic priming is more pronounced in female mice compared with male mice, and is closely regulated by circulating gonadal hormones in both sexes.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Contribution of gonadal hormones profoundly influences hyperalgesic priming in female and male mice. A, Hyperalgesic priming model with spinal PGE2 injection in WT female, OVX, and OVX+E (B) GdX, and (C) WT male, GdX, and GdX-T C57BL mice. B, The disparity in timelines between GDX animals and those animals that are naive or GdX-T. Arrows indicate injection time points for IL-6 and PGE2. Repeated-measures ANOVA with Bonferroni post hoc test: A, ***p < 0.001; ****p < 0.0001, for OVX-E compared with female; ★★p < 0.01 for OVX compared with female; C, ***p < 0.001; ★★p < 0.01 for GdX-T compared with male; n = 5 or 6. ★★★★p < 0.0001.

Translation regulation plays a key role in the development of hyperalgesic priming (Price and Inyang, 2015; Khoutorsky and Price, 2018). In previous experiments that were mostly done in male animals, we have shown that inhibition of cap-dependent translation at the time of initiation blocks the development of hyperalgesic priming (Melemedjian et al., 2010, 2014; Asiedu et al., 2011; Moy et al., 2017). Inhibition of cap-dependent translation during the maintenance phase fails to reverse established priming (Asiedu et al., 2011). In concordance with previous experiments (Melemedjian et al., 2010, 2014; Asiedu et al., 2011), the cap-dependent translation inhibitor 4EGI-1 (10 µg) given intrathecally immediately before PGE2 stimulation did not affect PGE2-induced mechanical hypersensitivity in males (repeated-measures ANOVA; F(8,64) = 0.3153; p = 0.9575; n = 5; Fig. 3A). In stark contrast, 4EGI-1 dramatically reduced the persistence of PGE2 precipitated mechanical hypersensitivity in females (repeated-measures ANOVA; F(8,64) = 10.60; p < 0.0001; n = 5; Fig. 3B). We next evaluated whether the difference between males and females in the regulation of maintenance of hyperalgesic priming was defined by gonadal hormone status. Removal of circulating E-2 using OVX females abolished the influence of 4EGI-1 on the hyperalgesic priming (repeated-measures ANOVA; F(9,90) = 0.7394; p = 0.6719; n = 6; Fig. 3C). These results indicate that the magnitude and maintenance of chronic pain are regulated by gonadal hormones in male and female mice and that the enhanced priming effect seen in intact female mice is dependent on translation regulation at the level of the DRG and/or SC. Interestingly, previous work done entirely in male rodents suggested that translation regulation events at the level of the DRG and/or SC were not involved in maintenance of hyperalgesic priming (Asiedu et al., 2011; Ferrari et al., 2015).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Spinal local translation only contributes to hyperalgesic priming in intact female mice. A, Hyperalgesic priming model with spinal PGE2 injection in WT male, (B) WT female, and (C) OVX mice. 4EGI-1 (10 µg) or vehicle was administered spinally at 30 min before PGE2 injection. Arrows indicate injection time points for IL-6 and 4EGI-1/PGE2. Repeated-measures ANOVA with Bonferroni post hoc test: ****p < 0.0001. n = 5 or 6.

A female-specific role for sensory neuronal Prlr in hyperalgesic priming

Responsiveness to PRL in sensory neurons is substantially higher in females (>40 fold) than in males (Patil et al., 2013b, 2019a,b), and strictly controlled by E-2 (Diogenes et al., 2006; Patil et al., 2019b). Endogenous and extrapituitary PRL is elevated in paw and SC after inflammation and surgical injury (Scotland et al., 2011; Patil et al., 2013a). Accordingly, we examined whether mimicking the presence of endogenous PRL after injury could prolong mechanical hypersensitivity induced by spinal PGE2 in both females and males. To do this, we primed the nociceptive pathway with a single injection of exogenous PRL (1 µg) intraplantarly (this PRL dosage is active in females but not males) (Patil et al., 2019b) and precipitated hyperalgesic priming with intrathecal PGE2 at 1 d after PRL treatment (Fig. 4A). We were able to administer PGE2 at 24 h after intraplantar PRL because 1 µg PRL produces mechanical hypersensitivity for only ∼3–4 h in females (Patil et al., 2019b). PGE2 evoked mechanical hypersensitivity was substantially longer lasting in PRL-treated female mice compared with vehicle-primed females (repeated-measures ANOVA; F(6,60) = 6.398; p < 0.0001; n = 6; Fig. 4C), but this was not the case in male mice (repeated-measures ANOVA; F(4,40) = 0.2318; p = 0.9189; n = 5–7; Fig. 4B).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Peripheral PRL only induces hyperalgesic priming in female mice. A, Schematic of the PRL-induced hyperalgesic priming model. BL, Baseline measurements after PRL-induced hypersensitivity is fully resolved. Brown arrows indicate injection time points. Blue arrows indicate post-PGE2 treatment mechanical nociception measurement time points. B, C, Hyperalgesic priming model; PRL or vehicle priming into paw and PGE2 injection into SC of male (B) or female (C) C57BL mice. Arrows indicate injection time points for PGE2. Repeated-measures ANOVA with Bonferroni post hoc test: ***p < 0.001; ****p < 0.0001. n = 5–7.

Our present findings suggest that a translation regulation event at the spinal level is critical for enhanced pain chronification in female mice. Our previous work demonstrated that Prlr signaling in the central terminals of nociceptors is important for acute pain models, specifically mechanical hypersensitivity in response to inflammation and injury in females (Patil et al., 2019b). This sex difference can be accounted for by increased translation of Prlr mRNA in central terminals of female mice (Patil et al., 2019b), suggesting transport of this mRNA to central terminals of nociceptors. To gain better insight into regulation of Prlr mRNA localization, we used Prlrfl/fl mice and crossed them with Nav1.8cre/− animals to generate a Nav1.8cre/−/Prlrfl/fl (Prlr CKO) in a set of sensory neurons (Fig. 5A). The Prlrfl/fl line has inverse lox sites; hence, Cre recombination ablates the Prlr gene and activates GFP expression in targeted cells driven by the Prlr promoter (Fig. 5A). Analysis of the Prlr CKO showed that the truncated transgene Prlr mRNA contains the entire 5′-UTR; four exons and an intron between exons 1 and 4 (EI–EIV) and GFP, but it does not have the remaining Prlr exons or the 3′-UTR (Fig. 5A). Accordingly, we observed that RT-PCR with Prlr-F and GFP-R1 primers (Fig. 5A, red arrows) produced a 2500 bp band containing an intron sequence from total RNA of female Prlr CKO, but not Prlrfl/fl (Fig. 5C).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Evidence for translocation of Prlr mRNA to sensory neuronal peripheral and central terminals in female mice. A, Schematic of Prlrfl/fl and Nav1.8cre/-/Prlrfl/fl (Prlr CKO) genes and corresponding transcribed mRNA from these genes. Location of Prlr-F and GFP-R1 (red arrows) and GFP-F and GFP-R2 (blue arrow). B, Representative panel for PCR of PGP9.5 mRNA (Uchl1 gene) from total RNA isolated from DRG and hindpaws (HP) of Prlrfl/fl (Con) and Prlr CKO female mice. B′, Quantification of data shown in B for Prlr CKO female mice (**p < 0.01; n = 3). C, Representative panel for PCR of hybrid 2500 bp Prlr mRNA using Prlr-F (exon 4) and GFP-R1 primers (see A) for DRG and SC total RNA isolated from Prlrfl/fl (Con) and Prlr CKO of female mice. C′, Quantification of data shown in C for Prlr CKO female mice (**p < 0.01; n = 3). D, Representative panel for PCR of GFP mRNA using GFP-F and GFP-R2 primers (see A) for DRG and SC total RNA isolated from Prlrfl/fl (Con) and Prlr CKO of female mice. D′, Quantification of data shown in D for Prlr CKO female mice (*p < 0.05; n = 3). E, Representative panel for PCR of GFP mRNA using GFP-F and GFP-R2 primers (see A) for DRG and HP total RNA isolated from Prlrfl/fl (Con) and Prlr CKO of female mice. E′, Quantification of data shown in E for Prlr CKO female mice (**p < 0.01; n = 3).

The unique splicing of EI-EIV and GFP for Prlr mRNA in Prlr CKO mice allowed us to detect localization of this hybrid Prlr mRNA synthesized from Prlr gene promoter in sensory neuronal cell bodies, as well as peripheral and central terminals. For these experiments, we also used a positive control, PGP9.5 mRNA (Uchl1 gene), which undergoes axonal transport in DRG neurons (Willis et al., 2005, 2007). Uchl1 mRNA was found in the hindpaw, but at an apparently lower level than observed in the DRG (unpaired two-tailed t test; t = 6.521 df = 4; Figs. 5B,B'). The hybrid Prlr mRNA in sensory neuronal cell bodies (DRG) and sensory neuronal central terminals (SC) was detected by amplification of the 2500 bp band from total RNA isolated from DRG and SC tissues of Prlr CKO (Fig. 5C). This 2500 bp band was not noticed in the Prlrfl/fl mouse line (Fig. 5C). Interestingly, the 2500 bp PCR product was detected in SC mRNA, suggesting constitutive axonal transport of Prlr mRNA (Fig. 5C). Moreover, hybrid Prlr mRNA was at significantly higher levels in SC compared with DRG (unpaired two-tailed t test; t = 4.797 df = 4; Fig. 5C'). To confirm this result with different primers, we PCR-amplified GFP (253 bp band) with GFP-F and GFP-R2 primers (Fig. 5A, blue arrows), using DRG and SC total RNA from Prlrfl/fl and Prlr CKO mice. GFP mRNA was detected not only in DRG of Prlr CKO females, but also in SC (Fig. 5D), and it was at higher density in SC compared with DRG (unpaired two-tailed t test; t = 3.608 df = 4; Fig. 5D'). To examine translocation of Prlr mRNA to peripheral terminals, we examined the presence of GFP mRNA in hindpaw tissues of Prlr CKO mice (Fig. 5E). Again, GFP mRNA in Prlr CKO was at higher levels in hindpaw compared with DRG tissues (unpaired two-tailed t test; t = 5.036 df = 4; Fig. 5E'). These findings suggest that female Prlr mRNA is extensively translocated to sensory neuron peripheral and central terminals, likely via an element in the 5′ UTR of the mRNA that is preserved in the transgene.

Next, we used Prlr CKO mice to examine the contribution of sensory neuronal Prlr to the regulation of the development of chronic pain in females and males. Prlr ablation in male sensory neurons did not affect either the initiation or persistent phase in the hyperalgesic priming model (repeated-measures ANOVA; F(12,66) = 9.445; p < 0.001; n = 4-6; Fig. 6A). In contrast, Prlr CKO female mice showed both a significant reduction in mechanical hypersensitivity in response to IL-6 injection and these mice also showed a greatly reduced response to PGE2 injection (persistent phase) compared with Prlrfl/fl mice (repeated-measures ANOVA; F(12,120) = 1.309, p = 0.2219; n = 5-7; Fig. 6B). We conclude from this experiment that Prlr in sensory neurons plays a key role in initiation and maintenance of chronic pain in female, but not male, mice.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Regulation of hyperalgesic priming by sensory neuronal Prlr selectively in female mice. A, B, Hyperalgesic priming model with peripheral IL-6/Veh and spinal PGE2 in Prlrfl/fl (Prlr-lox; control) and Nav1.8cre/-/Prlrfl/fl (Prlr CKO) in male (A) and female (B) mice. Arrows indicate injection time points for IL-6/Veh and PGE2. Repeated-measures ANOVA with Bonferroni post hoc test: A, ****p < 0.001, for Prlr-lox compared with Veh-Prlr-lox; and ★★★★p < 0.0001; ★★★p < 0.001, for Prlr CKO compared with Veh-Prlr-lox. B, *p < 0.05; **p < 0.01; ***p < 0.001. n = 4–7.

Prlr signaling and the initiation and maintenance of hyperalgesic priming in female mice

Ablation of Prlr in sensory neurons does not allow for identification of peripheral or central sites driving hyperalgesic priming or the time course of when Prlr signaling occurs during hyperalgesic priming. To explore this in detail, the Prlr antagonist ΔPRL (Rouet et al., 2010; Patil et al., 2019b), was delivered at different locations and time points. A single injection of the antagonist ΔPRL (5 µg) into the paw immediately before the intraplantar IL-6 priming injection did not affect mechanical hypersensitivity in response to the IL-6 injection (Fig. 7A). However, there was a significant reduction in mechanical hypersensitivity during the persistent, post-PGE2 phase in animals that received ΔPRL compared with those that received the vehicle. These ΔPRL-treated female mice returned to baseline levels of mechanical sensitivity within 2 d of the PGE2 injection (repeated-measures ANOVA; F(30,195) = 6.043; p < 0.0001; n = 5 or 6; Fig. 7A). Intrathecal administration of ΔPRL (5 µg) immediately before intraplantar IL-6 led to a transient reduction in mechanical hypersensitivity for <3 h following intraplantar IL-6 injection (Fig. 7A). The degree of mechanical hypersensitivity following PGE2 injection was almost identical to that observed with intraplantar administration of ΔPRL. We then evaluated the role of Prlr signaling in the maintenance of hyperalgesic priming with intraplantar or intrathecal administration of ΔPRL (5 µg) before PGE2 administration. Blockage of Prlr signaling in the paw by intraplantar injection of ΔPRL before the injection of PGE2 did not influence mechanical hypersensitivity magnitude or duration. In contrast, intrathecal administration of ΔPRL coupled with intrathecal PGE2 administration led to inhibition of mechanical hypersensitivity and a faster return to baseline (repeated-measures ANOVA; F(30,210) = 7.192; p < 0.0001; n = 5 or 6; Fig. 7B).

Figure 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 7.

Regulation of the initiation and maintenance of hyperalgesic priming by peripheral and spinal Prlr in female mice. Hyperalgesic priming model in female mice with peripheral IL-6 and spinal PGE2. A, Schematic of injection locations and timing. B, Vehicle (no ΔPRL), Prlr antagonist (ΔPRL; 5 µg) was coadministered with IL-6 in paw or SC. C, Schematic of injection locations and timing. D, Vehicle (no ΔPRL) was injected into paw. ΔPRL (5 µg) was given into the paw or SC 30 min before spinal PGE2. Repeated-measures ANOVA with Bonferroni post hoc test: *p < 0.05; ****p < 0.0001, for ΔPRL intrathecally compared with no ΔPRL; and ★★★★p < 0.0001; ★p < 0.05, for ΔPRL intraplantarly compared with no ΔPRL; n = 5–7).

The conventional view is that endogenous PRL comes almost exclusively from the pituitary gland (Ben-Jonathan et al., 2008). However, extrapituitary sources for PRL have been reported, and these PRL sources are especially abundant in humans (Ben-Jonathan et al., 1996). In rodents, inflammation and tissue injury cause an increase in PRL in the paw and SC (Scotland et al., 2011; Patil et al., 2013a). We examined whether endogenous pituitary PRL is involved in the regulation of pain chronicity in male and female mice. Circulating PRL that has originated in the pituitary can be removed by either hypophysectomy (Green et al., 2016) or systemic treatment with bromocriptine (Grattan, 2015). Both approaches have downsides, but we opted to use the systemic bromocriptine approach because bromocriptine is used in clinical studies and hypophysectomy drastically affects gonadal hormone production. We systemically treated both male and female mice with bromocriptine as previously described (Yip et al., 2012). Removal of endogenous pituitary PRL did not influence mechanical hypersensitivity during the IL-6 phase of hyperalgesic priming initiation in male mice but did slightly prolong the PGE2 precipitated hypersensitivity (repeated-measures ANOVA; F(10,90) = 2.980; p = 0.0028; n = 5 or 6; Fig. 8A). In female mice, the IL-6 response was enhanced in the bromocriptine-treated females, but the priming response to PGE2 was equivalent in vehicle and bromocriptine-treated mice (repeated-measures ANOVA; F(14,126) = 3.127; p = 0.0003; n = 5 or 6; Fig. 8B). Collectively, these results suggest that endogenous extrapituitary PRL signaling plays a key role in hyperalgesic priming in female mice. During initiation of chronic pain, this source can be peripheral or central, but the crucial source of PRL during the maintenance of pain chronicity is likely central.

Figure 8.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 8.

Lack of effect of systemic bromocriptine on hyperalgesic priming in female and male mice. A, B, Hyperalgesic priming model with peripheral IL-6 and spinal PGE2 in vehicle and bromocriptine (i.p.; BrCre) treatments of male (A) and female (B) mice. Arrows indicate injection time points for IL-6 and PGE2. Repeated-measures ANOVA with Bonferroni post hoc test: ***p < 0.001; ****p < 0.0001. n = 5 or 6.

Discussion

Studies in both animals and humans demonstrate sexually dimorphic mechanisms controlling the development and resolution of chronic pain (Joseph et al., 2003; Sorge et al., 2015; Nasir et al., 2016; Taves et al., 2016; Lopes et al., 2017; Rosen et al., 2017, 2019; Mapplebeck et al., 2018; Paige et al., 2018; Dance, 2019; North et al., 2019; Patil et al., 2019b; Ray et al., 2019). Among these sex differences, several factors have been discovered that drive chronic pain specifically in males (Sorge et al., 2015; Taves et al., 2016; Mapplebeck et al., 2018; Megat et al., 2018; Paige et al., 2018; Shiers et al., 2018; Martin et al., 2019), but relatively little is known about such chronic pain mechanisms in females. There is evidence that these mechanisms are closely regulated by gonadal hormones (Traub and Ji, 2013). For instance, the apparent male-specific effect of microglia-driven P2X4 signaling in neuropathic pain can be conferred to females with testosterone treatment (Sorge et al., 2015). In humans, sex differences in tibial nerve transcriptomes also demonstrate a signature for gonadal hormone influence on sensory neuronal transcriptomes across the lifespan in females (Ray et al., 2019). Experiments described here clearly demonstrate differential roles of gonadal hormones in development of chronicity in painful conditions with estrogen exacerbating priming effects and testosterone playing a protective role.

Additionally, we demonstrated that translation regulation plays a sex-specific role in the maintenance of chronic pain in female mice. This is especially relevant considering that translation control mechanisms are known contributors to the sensitization of nociceptors (Khoutorsky and Price, 2018; Megat and Price, 2018). Our previous work demonstrated that disruption of translation regulation signaling in the periphery or SC was only capable of interfering with hyperalgesic priming if these treatments were given at the time of the priming event (Melemedjian et al., 2010, 2014; Asiedu et al., 2011). However, these previously published experiments were done entirely in male mice. Our data suggest that targeting these translation regulation mechanisms for the treatment of pain may have additional therapeutic benefits in women. A potential explanation for this differential effect on translation machinery in females is an effect of estrogen on translation machinery (Bronson et al., 2010; Ochnik et al., 2016). E-2-dependent connections between translational control of the suppressor of cytokine signaling and mTOR phosphorylation (Augusto et al., 2010) or regulation of Rheb signaling (Pochynyuk et al., 2006) have been proposed (Matthews et al., 2005; Arbocco et al., 2016). These signaling pathways also play key roles in the excitability of nociceptors (Moy et al., 2017; Khoutorsky and Price, 2018; Megat et al., 2019a,b) and may play a more prominent role in the maintenance of persistent nociceptor plasticity in females than males.

Previous work indicates that sex-dependent mechanisms regulating hypersensitivity in inflammatory and neuropathic pain conditions can be attributed to distinct immune cell types: microglia in males (Sorge et al., 2011, 2015, Taves et al., 2016; Paige et al., 2018) and T cells in females (Sorge et al., 2015). Importantly, there is an opinion that these cells are regulated by gonadal hormones. Together, key molecules involved in sex-dependent regulation of the initiation, maintenance, and resolution would need to (1) be controlled by gonadal hormones, (2) induced by injury, (3) regulate immune cells, (4) undergo local translation control, and (5) be capable of regulating many other genes. The neuroendocrine hormone PRL and its receptor Prlr fit all these requirements. First, Prlr-mediated PRL effects are sex- and gonadal hormone-dependent in many tissues and cell types, including sensory neurons (Torner et al., 2001; Ben-Jonathan et al., 2008; Belugin et al., 2013; Patil et al., 2013a, 2019a,b). Second, many clinical and preclinical studies show that endogenous release of PRL from both pituitary and extrapituitary origins is induced by inflammation and tissue injury (Chernow et al., 1987; Noreng et al., 1987; Ben-Jonathan et al., 1996; Yardeni et al., 2007; Scotland et al., 2011; Patil et al., 2013a). Third, PRL is an effective direct and/or indirect activator of immune cells, especially macrophages and T cells (Matera et al., 2001; Savino et al., 2016; Tang et al., 2017). Moreover, many chronic autoimmune diseases affect females more frequently than males, and a potential role for PRL may in part explain this phenomenon for certain autoimmune diseases, such as lupus (Tang et al., 2017; Rizzetto et al., 2018). Fourth, translational regulation of Prlr in sensory neurons has been suggested in our previous work (Patil et al., 2019b), and herein we show evidence in support of the translocation of Prlr mRNA to peripheral and central terminals of female or male sensory neurons where it could be translated in a female sex hormone-specific fashion (Patil et al., 2019b). Finally, Prlr activation leads to epigenetic changes and transcription regulation of many genes via the STAT5 pathway (Bole-Feysot et al., 1998; Ben-Jonathan et al., 2008). The data presented here are one of the first demonstrations of a female-specific chronic pain initiation and maintenance mechanism acting directly on sensory neurons. Another is calcitonin gene-related peptide, which is released from sensory neurons, but its site of action to produce pain specifically in female mice is not known (Avona et al., 2019). Our findings using a sensory neuron-specific KO of Prlr combined with pharmacological antagonism of Prlr at specific sites suggests that Prlr signaling in sensory neuronal terminals of the SC controls initiation and maintenance of a chronic pain state in female mice. Having said this, we cannot rule out the possible influence of immune cells in our observations, including immune cells as a possible source of PRL that acts on Prlr in the setting of hyperalgesic priming in female mice.

A previous study in rats demonstrated that hyperalgesic priming to carrageenan does not occur in females (Joseph et al., 2003). Subsequent studies in mice and rats have shown additional sexual dimorphisms (Megat et al., 2018; Paige et al., 2018; Inyang et al., 2019), across the lifespan (Moriarty et al., 2019), but none of them has observed a similar absence of priming in female rodents. Indeed, our work shows, at least with IL-6 as the priming stimulus, that the magnitude and duration of the response to PGE2 given peripherally or intrathecally are longer in female mice than in male mice.

Previous work from our laboratory (Patil et al., 2013a, 2019a,b) and other groups (Chen et al., 2020b) has established that PRL signaling to nociceptor PRL receptors plays an important role in promoting pain in response to injury, specifically in female rodents (Chen et al., 2020a). Our findings presented here extend this work to show that PRL signaling to nociceptors promotes development of chronic pain, also specifically in females. Interestingly, there is literature linking PRL to migraine (Silberstein, 1992; Cavestro et al., 2006), and a recent clinical study demonstrates that reducing PRL levels leads to resolution of headache, suggesting a causative role (Oliveira et al., 2020). These preclinical and clinical results suggest that targeting PRL signaling may be a treatment avenue for certain types of chronic pain, but likely only in women.

In conclusion, our findings demonstrate that sensory neuronal Prlr signaling relies on gonadal hormones and translation mechanisms to contribute to a female-specific regulation of the initiation and maintenance of pain chronicity. These results add a new depth to our understanding of sexually dimorphic signaling pathways involved in chronic pain development. Additionally, our data further substantiate the critical role that the neuroendocrine system and translation regulation play in nociceptor and nociceptive circuit excitability in response to a broad variety of important physiological stimuli.

Footnotes

  • The authors declare no competing financial interests.

  • This work was supported by National Institute of Neurological Disorders and Stroke/National Institutes of Health NS102161 to T.J.P. and A.N.A.; National Institutes of Health/National Institute of General Medical Sciences GM112747 to A.N.A.; National Institute of Neurological Disorders and Stroke/National Institutes of Health NS065926 to T.J.P.; National Institute of Neurological Disorders and Stroke/National Institutes of Health NS113457 to C.P.; and University of Texas BRAIN Pilot Program ID 1503083 to G.D. and A.N.A. We thank Dr. Dustin Green for advice on the experimental strategy; and Dr. Florence Boutillon for producing recombinant PRL and Δ1-9-G129R-hPRL (ΔPRL).

  • Correspondence should be addressed to Armen N. Akopian at Akopian{at}UTHSCSA.edu or Theodore J. Price at Theodore.Price{at}utdallas.edu

References

  1. ↵
    1. Aley KO,
    2. Messing RO,
    3. Mochly-Rosen D,
    4. Levine JD
    (2000) Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isozyme of protein kinase C. J Neurosci 20:4680–4685. pmid:10844037
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Arbocco FC,
    2. Sasso CV,
    3. Actis EA,
    4. Caron RW,
    5. Hapon MB,
    6. Jahn GA
    (2016) Hypothyroidism advances mammary involution in lactating rats through inhibition of PRL signaling and induction of LIF/STAT3 mRNAs. Mol Cell Endocrinol 419:18–28. doi:10.1016/j.mce.2015.09.023 pmid:26472537
    OpenUrlCrossRefPubMed
  3. ↵
    1. Asiedu MN,
    2. Tillu DV,
    3. Melemedjian OK,
    4. Shy A,
    5. Sanoja R,
    6. Bodell B,
    7. Ghosh S,
    8. Porreca F,
    9. Price TJ
    (2011) Spinal protein kinase M zeta underlies the maintenance mechanism of persistent nociceptive sensitization. J Neurosci 31:6646–6653. doi:10.1523/JNEUROSCI.6286-10.2011 pmid:21543593
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Augusto TM,
    2. Bruni-Cardoso A,
    3. Damas-Souza DM,
    4. Zambuzzi WF,
    5. Kühne F,
    6. Lourenço LB,
    7. Ferreira CV,
    8. Carvalho HF
    (2010) Oestrogen imprinting causes nuclear changes in epithelial cells and overall inhibition of gene transcription and protein synthesis in rat ventral prostate. Int J Androl 33:675–685. doi:10.1111/j.1365-2605.2009.01008.x pmid:19925618
    OpenUrlCrossRefPubMed
  5. ↵
    1. Avona A,
    2. Burgos-Vega C,
    3. Burton MD,
    4. Akopian AN,
    5. Price TJ,
    6. Dussor G
    (2019) Dural calcitonin gene-related peptide produces female-specific responses in rodent migraine models. J Neurosci 39:4323–4331. doi:10.1523/JNEUROSCI.0364-19.2019 pmid:30962278
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Belugin S,
    2. Diogenes AR,
    3. Patil MJ,
    4. Ginsburg E,
    5. Henry MA,
    6. Akopian AN
    (2013) Mechanisms of transient signaling via short and long prolactin receptor isoforms in female and male sensory neurons. J Biol Chem 288:34943–34955. doi:10.1074/jbc.M113.486571 pmid:24142695
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Ben-Jonathan N,
    2. Mershon JL,
    3. Allen DL,
    4. Steinmetz RW
    (1996) Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639–669. doi:10.1210/edrv-17-6-639 pmid:8969972
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ben-Jonathan N,
    2. LaPensee CR,
    3. LaPensee EW
    (2008) What can we learn from rodents about prolactin in humans? Endocr Rev 29:1–41. doi:10.1210/er.2007-0017 pmid:18057139
    OpenUrlCrossRefPubMed
  9. ↵
    1. Berkley KJ
    (1997) Sex differences in pain. Behav Brain Sci 20:371–380; discussion 435-513. doi:10.1017/s0140525x97221485 pmid:10097000
    OpenUrlCrossRefPubMed
  10. ↵
    1. Bernichtein S,
    2. Kayser C,
    3. Dillner K,
    4. Moulin S,
    5. Kopchick JJ,
    6. Martial JA,
    7. Norstedt G,
    8. Isaksson O,
    9. Kelly PA,
    10. Goffin V
    (2003) Development of pure prolactin receptor antagonists. J Biol Chem 278:35988–35999. doi:10.1074/jbc.M305687200 pmid:12824168
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Bole-Feysot C,
    2. Goffin V,
    3. Edery M,
    4. Binart N,
    5. Kelly PA
    (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225–268. doi:10.1210/edrv.19.3.0334 pmid:9626554
    OpenUrlCrossRefPubMed
  12. ↵
    1. Bronson MW,
    2. Hillenmeyer S,
    3. Park RW,
    4. Brodsky AS
    (2010) Estrogen coordinates translation and transcription, revealing a role for NRSF in human breast cancer cells. Mol Endocrinol 24:1120–1135. doi:10.1210/me.2009-0436 pmid:20392875
    OpenUrlCrossRefPubMed
  13. ↵
    1. Brown RS,
    2. Kokay IC,
    3. Phillipps HR,
    4. Yip SH,
    5. Gustafson P,
    6. Wyatt A,
    7. Larsen CM,
    8. Knowles P,
    9. Ladyman SR,
    10. LeTissier P,
    11. Grattan DR
    (2016) Conditional deletion of the prolactin receptor reveals functional subpopulations of dopamine neurons in the arcuate nucleus of the hypothalamus. J Neurosci 36:9173–9185. doi:10.1523/JNEUROSCI.1471-16.2016 pmid:27581458
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Caligioni CS
    (2009) Assessing reproductive status/stages in mice. Curr Protoc Neurosci Appendix 4:Appendix 4I. doi:10.1002/0471142301.nsa04is48 pmid:19575469
    OpenUrlCrossRefPubMed
  15. ↵
    1. Cavestro C,
    2. Rosatello A,
    3. Marino MP,
    4. Micca G,
    5. Asteggiano G
    (2006) High prolactin levels as a worsening factor for migraine. J Headache Pain 7:83–89. doi:10.1007/s10194-006-0272-8 pmid:16538425
    OpenUrlCrossRefPubMed
  16. ↵
    1. Chaplan SR,
    2. Bach FW,
    3. Pogrel JW,
    4. Chung JM,
    5. Yaksh TL
    (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55–63.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Chen Y,
    2. Navratilova E,
    3. Dodick DW,
    4. Porreca F
    (2020a) An emerging role for prolactin in female-selective pain. Trends Neurosci 43:635–648.
    OpenUrl
  18. ↵
    1. Chen Y,
    2. Moutal A,
    3. Navratilova E,
    4. Kopruszinski C,
    5. Yue X,
    6. Ikegami M,
    7. Chow M,
    8. Kanazawa I,
    9. Bellampalli SS,
    10. Xie J,
    11. Patwardhan A,
    12. Rice K,
    13. Fields H,
    14. Akopian A,
    15. Neugebauer V,
    16. Dodick D,
    17. Khanna R,
    18. Porreca F
    (2020b) The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females. Sci Transl Med 12:eaay7550.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Chernow B,
    2. Alexander HR,
    3. Smallridge RC,
    4. Thompson WR,
    5. Cook D,
    6. Beardsley D,
    7. Fink MP,
    8. Lake CR,
    9. Fletcher JR
    (1987) Hormonal responses to graded surgical stress. Arch Intern Med 147:1273–1278. pmid:3606284
    OpenUrlCrossRefPubMed
  20. ↵
    1. Childs GV,
    2. Unabia G,
    3. Miller BT,
    4. Collins TJ
    (1999) Differential expression of gonadotropin and prolactin antigens by GHRH target cells from male and female rats. J Endocrinol 162:177–187. doi:10.1677/joe.0.1620177 pmid:10425455
    OpenUrlAbstract
  21. ↵
    1. Dance A
    (2019) Why the sexes don't feel pain the same way. Nature 567:448–450. doi:10.1038/d41586-019-00895-3 pmid:30918396
    OpenUrlCrossRefPubMed
  22. ↵
    1. Diogenes A,
    2. Patwardhan AM,
    3. Jeske NA,
    4. Ruparel NB,
    5. Goffin V,
    6. Akopian AN,
    7. Hargreaves KM
    (2006) Prolactin modulates TRPV1 in female rat trigeminal sensory neurons. J Neurosci 26:8126–8136. doi:10.1523/JNEUROSCI.0793-06.2006 pmid:16885226
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Ferrari LF,
    2. Araldi D,
    3. Levine JD
    (2015) Distinct terminal and cell body mechanisms in the nociceptor mediate hyperalgesic priming. J Neurosci 35:6107–6116. doi:10.1523/JNEUROSCI.5085-14.2015 pmid:25878283
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Fillingim RB,
    2. King CD,
    3. Ribeiro-Dasilva MC,
    4. Rahim-Williams B,
    5. Riley JL
    (2009) Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain 10:447–485. doi:10.1016/j.jpain.2008.12.001 pmid:19411059
    OpenUrlCrossRefPubMed
  25. ↵
    1. Grattan DR
    (2015) 60 years of neuroendocrinology: the hypothalamo-prolactin axis. J Endocrinol 226:T101–T122. doi:10.1530/JOE-15-0213 pmid:26101377
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Green DP,
    2. Patil MJ,
    3. Akopian AN
    (2016) Influence of hypophysectomy, ovariectomy and gonadectomy on postoperative hypersensitivity in rats. Glob Anesth Perioper Med 2:171–175. doi:10.15761/GAPM.1000145 pmid:29399371
    OpenUrlCrossRefPubMed
  27. ↵
    1. Houghton LA,
    2. Lea R,
    3. Jackson N,
    4. Whorwell PJ
    (2002) The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 50:471–474. doi:10.1136/gut.50.4.471
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Inyang KE,
    2. McDougal TA,
    3. Ramirez ED,
    4. Williams M,
    5. Laumet G,
    6. Kavelaars A,
    7. Heijnen CJ,
    8. Burton M,
    9. Dussor G,
    10. Price TJ
    (2019) Alleviation of paclitaxel-induced mechanical hypersensitivity and hyperalgesic priming with AMPK activators in male and female mice. Neurobiol Pain 6:100037. doi:10.1016/j.ynpai.2019.100037 pmid:31650090
    OpenUrlCrossRefPubMed
  29. ↵
    1. Joseph EK,
    2. Parada CA,
    3. Levine JD
    (2003) Hyperalgesic priming in the rat demonstrates marked sexual dimorphism. Pain 105:143–150. doi:10.1016/s0304-3959(03)00175-1 pmid:14499430
    OpenUrlCrossRefPubMed
  30. ↵
    1. Khoutorsky A,
    2. Price TJ
    (2018) Translational control mechanisms in persistent pain. Trends Neurosci 41:100–114. doi:10.1016/j.tins.2017.11.006 pmid:29249459
    OpenUrlCrossRefPubMed
  31. ↵
    1. Kim JY,
    2. Megat S,
    3. Moy JK,
    4. Asiedu MN,
    5. Mejia GL,
    6. Vagner J,
    7. Price TJ
    (2016) Neuroligin 2 regulates spinal GABAergic plasticity in hyperalgesic priming, a model of the transition from acute to chronic pain. Pain 157:1314–1324.
    OpenUrlCrossRefPubMed
  32. ↵
    1. LeResche L,
    2. Mancl L,
    3. Sherman JJ,
    4. Gandara B,
    5. Dworkin SF
    (2003) Changes in temporomandibular pain and other symptoms across the menstrual cycle. Pain 106:253–261. doi:10.1016/j.pain.2003.06.001 pmid:14659508
    OpenUrlCrossRefPubMed
  33. ↵
    1. Liu TT,
    2. Qu ZW,
    3. Ren C,
    4. Gan X,
    5. Qiu CY,
    6. Hu WP
    (2016) Prolactin potentiates the activity of acid-sensing ion channels in female rat primary sensory neurons. Neuropharmacology 103:174–182. doi:10.1016/j.neuropharm.2015.07.016 pmid:26188144
    OpenUrlCrossRefPubMed
  34. ↵
    1. Lopes DM,
    2. Malek N,
    3. Edye M,
    4. Jager SB,
    5. McMurray S,
    6. McMahon SB,
    7. Denk F
    (2017) Sex differences in peripheral not central immune responses to pain-inducing injury. Sci Rep 7:16460. doi:10.1038/s41598-017-16664-z pmid:29184144
    OpenUrlCrossRefPubMed
  35. ↵
    1. Mapplebeck JC,
    2. Dalgarno R,
    3. Tu Y,
    4. Moriarty O,
    5. Beggs S,
    6. Kwok CH,
    7. Halievski K,
    8. Assi S,
    9. Mogil JS,
    10. Trang T,
    11. Salter MW
    (2018) Microglial P2X4R-evoked pain hypersensitivity is sexually dimorphic in rats. Pain 159:1752–1763. doi:10.1097/j.pain.0000000000001265 pmid:29927790
    OpenUrlCrossRefPubMed
  36. ↵
    1. Martin LJ,
    2. Acland EL,
    3. Cho C,
    4. Gandhi W,
    5. Chen D,
    6. Corley E,
    7. Kadoura B,
    8. Levy T,
    9. Mirali S,
    10. Tohyama S,
    11. Khan S,
    12. MacIntyre LC,
    13. Carlson EN,
    14. Schweinhardt P,
    15. Mogil JS
    (2019) Male-specific conditioned pain hypersensitivity in mice and humans. Curr Biol 29:192–201.e194. doi:10.1016/j.cub.2018.11.030 pmid:30639112
    OpenUrlCrossRefPubMed
  37. ↵
    1. Matera L,
    2. Mori M,
    3. Galetto A
    (2001) Effect of prolactin on the antigen presenting function of monocyte-derived dendritic cells. Lupus 10:728–734. doi:10.1191/096120301717164967 pmid:11721699
    OpenUrlCrossRefPubMed
  38. ↵
    1. Mathew PG,
    2. Dun EC,
    3. Luo JJ
    (2013) A cyclic pain: the pathophysiology and treatment of menstrual migraine. Obstet Gynecol Surv 68:130–140. doi:10.1097/OGX.0b013e31827f2496 pmid:23417219
    OpenUrlCrossRefPubMed
  39. ↵
    1. Matthews J,
    2. Almlof T,
    3. Kietz S,
    4. Leers J,
    5. Gustafsson JA
    (2005) Estrogen receptor-alpha regulates SOCS-3 expression in human breast cancer cells. Biochem Biophys Res Commun 335:168–174. doi:10.1016/j.bbrc.2005.07.057 pmid:16055089
    OpenUrlCrossRefPubMed
  40. ↵
    1. Megat S,
    2. Price TJ
    (2018) Therapeutic opportunities for pain medicines via targeting of specific translation signaling mechanisms. Neurobiol Pain 4:8–19. doi:10.1016/j.ynpai.2018.02.001
    OpenUrlCrossRef
  41. ↵
    1. Megat S,
    2. Shiers S,
    3. Moy JK,
    4. Barragan-Iglesias P,
    5. Pradhan G,
    6. Seal RP,
    7. Dussor G,
    8. Price TJ
    (2018) A critical role for dopamine D5 receptors in pain chronicity in male mice. J Neurosci 38:379–397. doi:10.1523/JNEUROSCI.2110-17.2017 pmid:29167404
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Megat S,
    2. Ray PR,
    3. Tavares-Ferreira D,
    4. Moy JK
    5. Sankaranarayanan I,
    6. Wanghzou A,
    7. Lou F,
    8. Barragan-Iglesias T,
    9. Campbell P,
    10. Dussor G,
    11. Price TJ
    (2019a) Differences between dorsal root and trigeminal ganglion nociceptors in mice revealed by translational profiling. J Neurosci 39:6829–6847.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Megat S,
    2. Ray PR,
    3. Moy JK,
    4. Lou TF,
    5. Barragan-Iglesias P,
    6. Li Y,
    7. Pradhan G,
    8. Wanghzou A,
    9. Ahmad A,
    10. Burton MD,
    11. North RY,
    12. Dougherty PM,
    13. Khoutorsky A,
    14. Sonenberg N,
    15. Webster KR,
    16. Dussor G,
    17. Campbell ZT,
    18. Price TJ
    (2019b) Nociceptor translational profiling reveals the Ragulator-Rag GTPase complex as a critical generator of neuropathic pain. J Neurosci 39:393–411. doi:10.1523/JNEUROSCI.2661-18.2018 pmid:30459229
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Melemedjian OK,
    2. Asiedu MN,
    3. Tillu DV,
    4. Peebles KA,
    5. Yan J,
    6. Ertz N,
    7. Dussor GO,
    8. Price TJ
    (2010) IL-6- and NGF-induced rapid control of protein synthesis and nociceptive plasticity via convergent signaling to the eIF4F complex. J Neurosci 30:15113–15123. doi:10.1523/JNEUROSCI.3947-10.2010 pmid:21068317
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Melemedjian OK,
    2. Tillu DV,
    3. Moy JK,
    4. Asiedu MN,
    5. Mandell EK,
    6. Ghosh S,
    7. Dussor G,
    8. Price TJ
    (2014) Local translation and retrograde axonal transport of CREB regulates IL-6-induced nociceptive plasticity. Mol Pain 10:45. doi:10.1186/1744-8069-10-45 pmid:24993495
    OpenUrlCrossRefPubMed
  46. ↵
    1. Mogil JS,
    2. Sorge RE,
    3. LaCroix-Fralish ML,
    4. Smith SB,
    5. Fortin A,
    6. Sotocinal SG,
    7. Ritchie J,
    8. Austin JS,
    9. Schorscher-Petcu A,
    10. Melmed K,
    11. Czerminski J,
    12. Bittong RA,
    13. Mokris JB,
    14. Neubert JK,
    15. Campbell CM,
    16. Edwards RR,
    17. Campbell JN,
    18. Crawley JN,
    19. Lariviere WR,
    20. Wallace MR, et al
    . (2011) Pain sensitivity and vasopressin analgesia are mediated by a gene-sex-environment interaction. Nat Neurosci 14:1569–1573. doi:10.1038/nn.2941 pmid:22019732
    OpenUrlCrossRefPubMed
  47. ↵
    1. Moriarty O,
    2. Tu YS,
    3. Sengar AS,
    4. Salter MW,
    5. Beggs S,
    6. Walker SM
    (2019) Priming of adult incision response by early-life injury: neonatal microglial inhibition has persistent but sexually dimorphic effects in adult rats. J Neurosci 39:3081–3093. doi:10.1523/JNEUROSCI.1786-18.2019 pmid:30796159
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Moy JK,
    2. Khoutorsky A,
    3. Asiedu MN,
    4. Black BJ,
    5. Kuhn JL,
    6. Barragan-Iglesias P,
    7. Megat S,
    8. Burton MD,
    9. Burgos-Vega CC,
    10. Melemedjian OK,
    11. Boitano S,
    12. Vagner J,
    13. Gkogkas CG,
    14. Pancrazio JJ,
    15. Mogil JS,
    16. Dussor G,
    17. Sonenberg N,
    18. Price TJ
    (2017) The MNK-eIF4E signaling axis contributes to injury-induced nociceptive plasticity and the development of chronic pain. J Neurosci 37:7481–7499. doi:10.1523/JNEUROSCI.0220-17.2017 pmid:28674170
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Nasir H,
    2. Mahboubi H,
    3. Gyawali S,
    4. Ding S,
    5. Mickeviciute A,
    6. Ragavendran JV,
    7. Laferriere A,
    8. Stochaj U,
    9. Coderre TJ
    (2016) Consistent sex-dependent effects of PKMzeta gene ablation and pharmacological inhibition on the maintenance of referred pain. Mol Pain 12:174480691667534. doi:10.1177/1744806916675347
    OpenUrlCrossRef
  50. ↵
    1. Nettleship JE,
    2. Jones TH,
    3. Channer KS,
    4. Jones RD
    (2007) Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation 116:2427–2434. doi:10.1161/CIRCULATIONAHA.107.708768
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Noreng MF,
    2. Jensen P,
    3. Tjellden NU
    (1987) Per- and postoperative changes in the concentration of serum thyreotropin under general anaesthesia, compared to general anaesthesia with epidural analgesia. Acta Anaesthesiol Scand 31:292–294. doi:10.1111/j.1399-6576.1987.tb02569.x pmid:3591253
    OpenUrlCrossRefPubMed
  52. ↵
    1. North RY,
    2. Li Y,
    3. Ray P,
    4. Rhines LD,
    5. Tatsui CE,
    6. Rao G,
    7. Johansson CA,
    8. Zhang H,
    9. Kim YH,
    10. Zhang B,
    11. Dussor G,
    12. Kim TH,
    13. Price TJ,
    14. Dougherty PM
    (2019) Electrophysiological and transcriptomic correlates of neuropathic pain in human dorsal root ganglion neurons. Brain 142:1215–1226. doi:10.1093/brain/awz063 pmid:30887021
    OpenUrlCrossRefPubMed
  53. ↵
    1. Ochnik AM,
    2. Peterson MS,
    3. Avdulov SV,
    4. Oh AS,
    5. Bitterman PB,
    6. Yee D
    (2016) Amplified in breast cancer regulates transcription and translation in breast cancer cells. Neoplasia 18:100–110. doi:10.1016/j.neo.2016.01.001 pmid:26936396
    OpenUrlCrossRefPubMed
  54. ↵
    1. Oliveira MD,
    2. Barea LM,
    3. Horn AP,
    4. Ongaratti BR,
    5. Soares JO,
    6. Araujo B,
    7. Santos TM,
    8. Rech CL,
    9. Pereira-Lima JF
    (2020) Resolution of headache after reduction of prolactin levels in hyperprolactinemic patients. Arq Neuropsiquiatr 78:28–33. doi:10.1590/0004-282x20190143
    OpenUrlCrossRef
  55. ↵
    1. Paige C,
    2. Maruthy GB,
    3. Mejia G,
    4. Dussor G,
    5. Price T
    (2018) Spinal inhibition of P2XR or p38 signaling disrupts hyperalgesic priming in male, but not female, mice. Neuroscience 385:133–142. doi:10.1016/j.neuroscience.2018.06.012 pmid:29913243
    OpenUrlCrossRefPubMed
  56. ↵
    1. Patil MJ,
    2. Green DP,
    3. Henry MA,
    4. Akopian AN
    (2013a) Sex-dependent roles of prolactin and prolactin receptor in postoperative pain and hyperalgesia in mice. Neuroscience 253:132–141. doi:10.1016/j.neuroscience.2013.08.035 pmid:23994182
    OpenUrlCrossRefPubMed
  57. ↵
    1. Patil MJ,
    2. Ruparel SB,
    3. Henry MA,
    4. Akopian AN
    (2013b) Prolactin regulates TRPV1, TRPA1, and TRPM8 in sensory neurons in a sex-dependent manner: contribution of prolactin receptor to inflammatory pain. Am J Physiol Endocrinol Metab 305:E1154–E1164. doi:10.1152/ajpendo.00187.2013 pmid:24022869
    OpenUrlCrossRefPubMed
  58. ↵
    1. Patil MJ,
    2. Hovhannisyan AH,
    3. Wangzhou A,
    4. Mecklenburg J,
    5. Koek W,
    6. Goffin V,
    7. Grattan D,
    8. Boehm U,
    9. Dussor G,
    10. Price TJ,
    11. Akopian AN
    (2019a) Prolactin receptor expression in mouse dorsal root ganglia neuronal subtypes is sex-dependent. J Neuroendocrinol 31:e12759. doi:10.1111/jne.12759 pmid:31231869
    OpenUrlCrossRefPubMed
  59. ↵
    1. Patil MJ,
    2. Belugin S,
    3. Mecklenburg J,
    4. Wangzhou A,
    5. Paige C,
    6. Barba-Escobedo PA,
    7. Boyd JT,
    8. Goffin V,
    9. Grattan D,
    10. Boehm U,
    11. Dussor G,
    12. Price TJ,
    13. Akopian AN
    (2019b) Prolactin regulates pain responses via a female-selective nociceptor-specific mechanism. iScience 20:449–465. doi:10.1016/j.isci.2019.09.039 pmid:31627131
    OpenUrlCrossRefPubMed
  60. ↵
    1. Pi X,
    2. Voogt JL
    (2002) Sex difference and estrous cycle: expression of prolactin receptor mRNA in rat brain. Brain Res Mol Brain Res 103:130–139. doi:10.1016/s0169-328x(02)00194-8 pmid:12106698
    OpenUrlCrossRefPubMed
  61. ↵
    1. Pochynyuk O,
    2. Medina J,
    3. Gamper N,
    4. Genth H,
    5. Stockand JD,
    6. Staruschenko A
    (2006) Rapid translocation and insertion of the epithelial Na+ channel in response to RhoA signaling. J Biol Chem 281:26520–26527. doi:10.1074/jbc.M603716200 pmid:16829523
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Price TJ,
    2. Inyang KE
    (2015) Commonalities between pain and memory mechanisms and their meaning for understanding chronic pain. Prog Mol Biol Transl Sci 131:409–434. doi:10.1016/bs.pmbts.2014.11.010 pmid:25744681
    OpenUrlCrossRefPubMed
  63. ↵
    1. Ray PR,
    2. Khan J,
    3. Wangzhou A,
    4. Tavares-Ferreira D,
    5. Akopian AN,
    6. Dussor G,
    7. Price TJ
    (2019) Transcriptome analysis of the human tibial nerve identifies sexually dimorphic expression of genes involved in pain, inflammation, and neuro-immunity. Front Mol Neurosci 12:37. doi:10.3389/fnmol.2019.00037 pmid:30890918
    OpenUrlCrossRefPubMed
  64. ↵
    1. Rizzetto L,
    2. Fava F,
    3. Tuohy KM,
    4. Selmi C
    (2018) Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex. J Autoimmun 92:12–34. doi:10.1016/j.jaut.2018.05.008 pmid:29861127
    OpenUrlCrossRefPubMed
  65. ↵
    1. Rosen S,
    2. Ham B,
    3. Mogil JS
    (2017) Sex differences in neuroimmunity and pain. J Neurosci Res 95:500–508. doi:10.1002/jnr.23831 pmid:27870397
    OpenUrlCrossRefPubMed
  66. ↵
    1. Rosen SF,
    2. Ham B,
    3. Haichin M,
    4. Walters IC,
    5. Tohyama S,
    6. Sotocinal SG,
    7. Mogil JS
    (2019) Increased pain sensitivity and decreased opioid analgesia in T-cell-deficient mice and implications for sex differences. Pain 160:358–366. doi:10.1097/j.pain.0000000000001420 pmid:30335680
    OpenUrlCrossRefPubMed
  67. ↵
    1. Rouet V,
    2. Bogorad RL,
    3. Kayser C,
    4. Kessal K,
    5. Genestie C,
    6. Bardier A,
    7. Grattan DR,
    8. Kelder B,
    9. Kopchick JJ,
    10. Kelly PA,
    11. Goffin V
    (2010) Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc Natl Acad Sci USA 107:15199–15204. doi:10.1073/pnas.0911651107 pmid:20699217
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Savino W,
    2. Mendes-da-Cruz DA,
    3. Lepletier A,
    4. Dardenne M
    (2016) Hormonal control of T-cell development in health and disease. Nat Rev Endocrinol 12:77–89. doi:10.1038/nrendo.2015.168 pmid:26437623
    OpenUrlCrossRefPubMed
  69. ↵
    1. Scotland PE,
    2. Patil M,
    3. Belugin S,
    4. Henry MA,
    5. Goffin V,
    6. Hargreaves KM,
    7. Akopian AN
    (2011) Endogenous prolactin generated during peripheral inflammation contributes to thermal hyperalgesia. Eur J Neurosci 34:745–754. doi:10.1111/j.1460-9568.2011.07788.x pmid:21777304
    OpenUrlCrossRefPubMed
  70. ↵
    1. Shiers S,
    2. Pradhan G,
    3. Mwirigi J,
    4. Mejia G,
    5. Ahmad A,
    6. Kroener S,
    7. Price T
    (2018) Neuropathic pain creates an enduring prefrontal cortex dysfunction corrected by the type II diabetic drug metformin but not by gabapentin. J Neurosci 38:7337–7350. doi:10.1523/JNEUROSCI.0713-18.2018 pmid:30030404
    OpenUrlAbstract/FREE Full Text
  71. ↵
    1. Silberstein SD
    (1992) The role of sex hormones in headache. Neurology 42:37–42. pmid:1557190
    OpenUrlPubMed
  72. ↵
    1. Slade GD,
    2. Bair E,
    3. By K,
    4. Mulkey F,
    5. Baraian C,
    6. Rothwell R,
    7. Reynolds M,
    8. Miller V,
    9. Gonzalez Y,
    10. Gordon S,
    11. Ribeiro-Dasilva M,
    12. Lim PF,
    13. Greenspan JD,
    14. Dubner R,
    15. Fillingim RB,
    16. Diatchenko L,
    17. Maixner W,
    18. Dampier D,
    19. Knott C,
    20. Ohrbach R
    (2011) Study methods, recruitment, sociodemographic findings, and demographic representativeness in the OPPERA study. J Pain 12:T12–T26. doi:10.1016/j.jpain.2011.08.001 pmid:22074749
    OpenUrlCrossRefPubMed
  73. ↵
    1. Sorge RE,
    2. LaCroix-Fralish ML,
    3. Tuttle AH,
    4. Sotocinal SG,
    5. Austin JS,
    6. Ritchie J,
    7. Chanda ML,
    8. Graham AC,
    9. Topham L,
    10. Beggs S,
    11. Salter MW,
    12. Mogil JS
    (2011) Spinal cord Toll-like receptor 4 mediates inflammatory and neuropathic hypersensitivity in male but not female mice. J Neurosci 31:15450–15454. doi:10.1523/JNEUROSCI.3859-11.2011 pmid:22031891
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Sorge RE,
    2. Mapplebeck JC,
    3. Rosen S,
    4. Beggs S,
    5. Taves S,
    6. Alexander JK,
    7. Martin LJ,
    8. Austin JS,
    9. Sotocinal SG,
    10. Chen D,
    11. Yang M,
    12. Shi XQ,
    13. Huang H,
    14. Pillon NJ,
    15. Bilan PJ,
    16. Tu Y,
    17. Klip A,
    18. Ji RR,
    19. Zhang J,
    20. Salter MW, et al
    . (2015) Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat Neurosci 18:1081–1083. doi:10.1038/nn.4053 pmid:26120961
    OpenUrlCrossRefPubMed
  75. ↵
    1. Tang MW,
    2. Garcia S,
    3. Gerlag DM,
    4. Tak PP,
    5. Reedquist KA
    (2017) Insight into the endocrine system and the immune system: a review of the inflammatory role of prolactin in rheumatoid arthritis and psoriatic arthritis. Front Immunol 8:720. doi:10.3389/fimmu.2017.00720 pmid:28690611
    OpenUrlCrossRefPubMed
  76. ↵
    1. Taves S,
    2. Berta T,
    3. Liu DL,
    4. Gan S,
    5. Chen G,
    6. Kim YH,
    7. Van de Ven T,
    8. Laufer S,
    9. Ji RR
    (2016) Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: sex-dependent microglial signaling in the spinal cord. Brain Behav Immun 55:70–81. doi:10.1016/j.bbi.2015.10.006 pmid:26472019
    OpenUrlCrossRefPubMed
  77. ↵
    1. Torner L,
    2. Toschi N,
    3. Pohlinger A,
    4. Landgraf R,
    5. Neumann ID
    (2001) Anxiolytic and anti-stress effects of brain prolactin: improved efficacy of antisense targeting of the prolactin receptor by molecular modeling. J Neurosci 21:3207–3214. doi:10.1523/JNEUROSCI.21-09-03207.2001
    OpenUrlAbstract/FREE Full Text
  78. ↵
    1. Traub RJ,
    2. Ji Y
    (2013) Sex differences and hormonal modulation of deep tissue pain. Front Neuroendocrinol 34:350–366. doi:10.1016/j.yfrne.2013.07.002 pmid:23872333
    OpenUrlCrossRefPubMed
  79. ↵
    1. Unruh AM
    (1996) Gender variations in clinical pain experience. Pain 65:123–167. doi:10.1016/0304-3959(95)00214-6 pmid:8826503
    OpenUrlCrossRefPubMed
  80. ↵
    1. Willis D,
    2. Li KW,
    3. Zheng JQ,
    4. Chang JH,
    5. Smit A,
    6. Kelly T,
    7. Merianda TT,
    8. Sylvester J,
    9. van Minnen J,
    10. Twiss JL
    (2005) Differential transport and local translation of cytoskeletal, injury-response, and neurodegeneration protein mRNAs in axons. J Neurosci 25:778–791.
    OpenUrlAbstract/FREE Full Text
  81. ↵
    1. Willis DE,
    2. van Niekerk EA,
    3. Sasaki Y,
    4. Mesngon M,
    5. Merianda TT,
    6. Williams GG,
    7. Kendall M,
    8. Smith DS,
    9. Bassell GJ,
    10. Twiss JL
    (2007) Extracellular stimuli specifically regulate localized levels of individual neuronal mRNAs. J Cell Biol 178:965–980.
    OpenUrlAbstract/FREE Full Text
  82. ↵
    1. Yardeni IZ,
    2. Shavit Y,
    3. Bessler H,
    4. Mayburd E,
    5. Grinevich G,
    6. Beilin B
    (2007) Comparison of postoperative pain management techniques on endocrine response to surgery: a randomised controlled trial. Int J Surg 5:239–243. doi:10.1016/j.ijsu.2006.09.008 pmid:17660130
    OpenUrlCrossRefPubMed
  83. ↵
    1. Yip SH,
    2. Eguchi R,
    3. Grattan DR,
    4. Bunn SJ
    (2012) Prolactin signalling in the mouse hypothalamus is primarily mediated by signal transducer and activator of transcription factor 5b but not 5a. J Neuroendocrinol 24:1484–1491. doi:10.1111/j.1365-2826.2012.02357.x pmid:22775396
    OpenUrlCrossRefPubMed
Back to top

In this issue

The Journal of Neuroscience: 40 (37)
Journal of Neuroscience
Vol. 40, Issue 37
9 Sep 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Advertising (PDF)
  • Ed Board (PDF)
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Neuroendocrine Mechanisms Governing Sex Differences in Hyperalgesic Priming Involve Prolactin Receptor Sensory Neuron Signaling
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Neuroendocrine Mechanisms Governing Sex Differences in Hyperalgesic Priming Involve Prolactin Receptor Sensory Neuron Signaling
Candler Paige, Priscilla A. Barba-Escobedo, Jennifer Mecklenburg, Mayur Patil, Vincent Goffin, David R. Grattan, Gregory Dussor, Armen N. Akopian, Theodore J. Price
Journal of Neuroscience 9 September 2020, 40 (37) 7080-7090; DOI: 10.1523/JNEUROSCI.1499-20.2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
Neuroendocrine Mechanisms Governing Sex Differences in Hyperalgesic Priming Involve Prolactin Receptor Sensory Neuron Signaling
Candler Paige, Priscilla A. Barba-Escobedo, Jennifer Mecklenburg, Mayur Patil, Vincent Goffin, David R. Grattan, Gregory Dussor, Armen N. Akopian, Theodore J. Price
Journal of Neuroscience 9 September 2020, 40 (37) 7080-7090; DOI: 10.1523/JNEUROSCI.1499-20.2020
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • estrogen
  • nociceptor
  • prolactin
  • sex dimorphism
  • testosterone
  • translation regulation

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Research Articles

  • Oxidative stress-induced damage to the developing hippocampus is mediated by GSK3beta
  • Disruption of endosomal sorting in Schwann cells leads to defective myelination and endosomal abnormalities observed in Charcot-Marie-Tooth disease
  • Depolarizing NaV and hyperpolarizing KV channels are co-trafficked in sensory neurons
Show more Research Articles

Development/Plasticity/Repair

  • Oxidative stress-induced damage to the developing hippocampus is mediated by GSK3beta
  • The Nogo-66 Receptors NgR1 and NgR3 Are Required for Commissural Axon Pathfinding
  • Mllt11 Regulates Migration and Neurite Outgrowth of Cortical Projection Neurons during Development
Show more Development/Plasticity/Repair
  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
(JNeurosci logo)
(SfN logo)

Copyright © 2022 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.